Article Figures & Data
Tables
- Table 1.
Distributions of rheumatic diseases and therapies in 237 patients. Data are the mean ± SD or n (%).
Feature Disease Juvenile systemic lupus erythematosus 99 (41.8) Juvenile idiopathic arthritis 93 (39.2) Juvenile dermatomyositis 18 (7.6) Juvenile scleroderma 11 (4.6) Primary vasculitis 16 (6.8) Treatment Prednisone 90 (38) Dose, mg/day 17.4 ± 14.2 Dose, mg/kg/day 0.36 ± 0.32 Dose ≥ 20 mg/day 36 (40) Duration of glucocorticoid therapy, mo 43.1 ± 34.5 Immunosuppressant 143 (60.3) Methotrexate 74 (51.7) Azathioprine 43 (30.1) Cyclosporine 23 (16.1) Mycophenolate mofetil 13 (9.1) Leflunomide 6 (4.2) Cyclophosphamide 3 (2.1) - Table 2.
Seroprotection and seroconversion rates of influenza A (H1N1) 2009 vaccine in patients with rheumatic disease and controls.
Seroprotection Rate (titer ≥ 1/40) Seroconversion Rate, % (95% CI) N Before Immunization, % (95% CI) After Immunization, % (95% CI) Control 91 20.9 (12.6–29.3) 95.6 (91.4–99.8) 95.6 (91.4–99.8) JARD 237 22.4 (17.1–27.7) 81.4 (76.5–86.4)* 74.3 (68.7–79.9)* JSLE 99 20.2 (12.3–28.1) 73.7 (65.0–82.4)* 63.6 (54.1–73.1)* JIA 93 20.4 (12.2–28.6) 88.2 (81.6–94.8) 82.8 (75.1–90.5)* JDM 18 38.9 (16.4–61.4) 83.3 (66.1–100.5) 77.8 (58.6–97.0)* JScl 11 27.3 (1.0–53.6) 90.9 (73.9–107.9) 90.9 (73.9–107.9) Primary vasculitis 16 25.0 (13.8–46.2) 81.3 (62.2–100.4) 75 (53.8–96.2)* -
↵* p < 0.05. JARD: juvenile autoimmune rheumatic diseases; JSLE: juvenile systemic lupus erythematosus; JIA: juvenile idiopathic arthritis; JDM: juvenile dermatomyositis; JScl: juvenile scleroderma.
-
- Table 3.
Geometric mean titers and factor-increases in the geometric mean titer after influenza A (H1N1) 2009 vaccination in patients with juvenile autoimmune rheumatic disease and controls.
Geometric Mean Titer Factor-increase in Geometric Mean Titer (95% CI) N Before Immunization, % (95% CI) After Immunization, % (95% CI) Control 91 12.4 (9.7–15.7) 250.8 (196.3–320.3) 20.3 (15.6–26.4) JARD 237 11.4 (9.7–13.3) 147.2 (119.7–181.1)* 12.9 (10.7–15.7)* JSLE 99 10.9 (8.5–13.9) 91.1 (66.0–125.8)* 8.4 (6.3–11.2)* JIA 93 10.8 (8.4–13.8) 217.2 (159–296.7) 20.2 (14.8–27.5) JDM 18 15.3 (8.9–26.3) 201.6 (95.4–425.8) 13.2 (7.2–24.1) JScl 11 12.1 (6.0–24.2) 181.5 (70.2–469.4) 15.0 (6.3–35.9) Primary vasculitis 16 14.1 (6.8–29.2) 182.2 (68.1–487.4) 12.9 (5.9–28.2) -
↵* p < 0.05. JARD: juvenile autoimmune rheumatic diseases; JSLE: juvenile systemic lupus erythematosus; JIA: juvenile idiopathic arthritis; JDM: juvenile dermatomyositis; JScl: juvenile scleroderma.
-
- Table 4.
Multivariate logistic regression analyses including current treatment and lymphopenia as independent variables for seroconversion in patients with juvenile autoimmune rheumatic diseases after influenza A (H1N1) 2009 vaccination.
Variable OR (95% CI) p JSLE 0.36 (0.039–3.33) 0.368 JIA 0.45 (0.05–3.83) 0.47 JDM 0.51 (0.05–5.70) 0.586 Primary vasculitis 0.60 (0.05–7.21) 0.691 Glucocorticoid use 0.20 (0.06–0.70) 0.012 Concomitant use of glucocorticoid plus immunosuppressant 2.71 (0.90–8.20) 0.077 Lymphopenia 0.61 (0.27–1.38) 0.235 -
JSLE: juvenile systemic lupus erythematosus; JIA: juvenile idiopathic arthritis; JDM: juvenile dermatomyositis.
-
- Table 5.
Adverse events following influenza A (H1N1) 2009 vaccination in patients with juvenile autoimmune rheumatic diseases (JARD) and controls. Data are n (%).
Adverse Events JARD, n = 237 Control, n = 91 p Local reactions 60 (25.3) 21 (23.1) 0.78 Pain 43 (18.1) 21 (23.1) 0.35 Redness 9 (3.8) 2 (2.2) 0.73 Swelling 3 (1.3) 2 (2.2) 0.62 Itching 19 (8) 0 (0.0) 0.003 Systemic reactions 84 (35.4) 27 (29.7) 0.36 Arthralgia 31 (13.1) 2 (2.2) 0.002 Fever 13 (5.5) 3 (3.3) 0.57 Headache 41 (17.3) 18 (19.8) 0.63 Myalgia 27 (11.4) 6 (6.6) 0.22 Sore throat 9 (3.8) 5 (5.5) 0.54 Cough 16 (6.8) 5 (5.5) 0.8 Diarrhea 8 (3.4) 2 (2.2) 0.73 Rhinorrhea 19 (8) 3 (3.3) 0.15 Nasal congestion 13 (5.5) 3 (3.3) 0.57
